These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17910522)

  • 1. Atorvastatin: a safety and tolerability profile.
    Arca M
    Drugs; 2007; 67 Suppl 1():63-9. PubMed ID: 17910522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients.
    Newman C; Tsai J; Szarek M; Luo D; Gibson E
    Am J Cardiol; 2006 Jan; 97(1):61-7. PubMed ID: 16377285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients.
    Newman CB; Palmer G; Silbershatz H; Szarek M
    Am J Cardiol; 2003 Sep; 92(6):670-6. PubMed ID: 12972104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
    Golomb B; Evans M
    Drug Saf; 2006; 29(12):1191; author reply 1191-2. PubMed ID: 17147465
    [No Abstract]   [Full Text] [Related]  

  • 5. Atorvastatin: safety and tolerability.
    Athyros VG; Tziomalos K; Karagiannis A; Mikhailidis DP
    Expert Opin Drug Saf; 2010 Jul; 9(4):667-74. PubMed ID: 20553090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.
    Illingworth DR; Crouse JR; Hunninghake DB; Davidson MH; Escobar ID; Stalenhoef AF; Paragh G; Ma PT; Liu M; Melino MR; O'Grady L; Mercuri M; Mitchel YB;
    Curr Med Res Opin; 2001; 17(1):43-50. PubMed ID: 11464446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atorvastatin-induced acute elevation of hepatic enzymes and the absence of cross-toxicity of pravastatin.
    Liu Y; Cheng Z; Ding L; Fang F; Cheng KA; Fang Q; Shi GP
    Int J Clin Pharmacol Ther; 2010 Dec; 48(12):798-802. PubMed ID: 21084035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors.
    Molden E; Skovlund E; Braathen P
    Drug Saf; 2008; 31(7):587-96. PubMed ID: 18558792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute cholestatic hepatitis after atorvastatin reintroduction].
    de Castro ML; Hermo JA; Baz A; de Luaces C; Pérez R; Clofent J
    Gastroenterol Hepatol; 2006 Jan; 29(1):21-4. PubMed ID: 16393626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune hepatitis revealed by atorvastatin.
    Pelli N; Setti M; Ceppa P; Toncini C; Indiveri F
    Eur J Gastroenterol Hepatol; 2003 Aug; 15(8):921-4. PubMed ID: 12867804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
    LaRosa JC; Grundy SM; Waters DD; Shear C; Barter P; Fruchart JC; Gotto AM; Greten H; Kastelein JJ; Shepherd J; Wenger NK;
    N Engl J Med; 2005 Apr; 352(14):1425-35. PubMed ID: 15755765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tachyphylaxis and statin drugs.
    Stein JH; McBride PE
    Am J Cardiol; 2001 Mar; 87(5):674. PubMed ID: 11245286
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.
    Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M;
    Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of atorvastatin in heart transplant recipients.
    Patel DN; Pagani FD; Koelling TM; Dyke DB; Baliga RR; Cody RJ; Lake KD; Aaronson KD
    J Heart Lung Transplant; 2002 Feb; 21(2):204-10. PubMed ID: 11834348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute hepatic injury with atorvastatin: an unusual occurrence.
    Vishwakarma P; Nehra R; Kumar A
    Indian J Pharmacol; 2014; 46(3):343-4. PubMed ID: 24987187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of alternate-day dosing versus daily dosing of atorvastatin.
    Jafari M; Ebrahimi R; Ahmadi-Kashani M; Balian H; Bashir M
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8(2):123-6. PubMed ID: 12808485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of high-dose atorvastatin therapy.
    Waters DD
    Am J Cardiol; 2005 Sep; 96(5A):69F-75F. PubMed ID: 16126026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of HMG-CoA reductase inhibitors: focus on atorvastatin.
    Bernini F; Poli A; Paoletti R
    Cardiovasc Drugs Ther; 2001; 15(3):211-8. PubMed ID: 11713888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes.
    Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR
    J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones.
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2004 Jun; 93(11):1417-8, A9. PubMed ID: 15165929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.